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Review
Environmental health and infectious disease 
have been intertwined in the study of public 
health since at least the mid-1850s, when 
John Snow used an environmental map to 
determine origins of a London cholera out-
break, thus highlighting the concept of place 
as a determinant of infectious disease preva-
lence and transmission risks. Since that time, 
the fields of environmental health and infec-
tious disease have diverged in many regions, 
particularly in the United States, where these 
fields are currently treated as distinct entities, 
leading to separate research funding tracks 
and distinct training programs in schools of 
public health. Although environmental health 
research continues to contribute to under-
standing key factors rele vant to infectious 
diseases such as malaria, Lyme disease, and 
hanta virus pulmonary syndrome (Peterson 
et al., in press), environmental health research 
and practice predominantly focus on chemical 
and physical agents despite the inherent role 
of the environment in pathogen dynamics 
and host response. 
Environmental health’s focus on the abi-
otic factors of toxicology has meant that the 
field produces relatively little research on how 
pathogens and toxic agents interact to increase 
risks and severity of diseases and dysfunc-
tions. Several of the major toxicant exposures 
studied within environmental health research 
alter risks for pathogen transmission and dis-
ease severity. Exposures to toxic agents may 
lead to immuno toxic changes in hosts that 
reduce the threshold for infection, increase the 
persistence of an infection, increase pathogen 
shedding, and alter the severity and burden 
of infectious disease. Pathogens can modify 
inflammatory pathways and other responses 
induced by environmental toxicants and 
modify the likelihood and severity of chronic 
disease progression. For these reasons, in this 
article we argue that infectious diseases should 
be considered explicitly within the toxicologi-
cal framework to capture interactions between 
pathogens and toxicants that contribute to 
the etiology of diseases often assumed to be of 
either pathogen or toxicant origin. 
In this article, specific examples high-
light the importance of unifying infectious 
disease and toxicant research. In particular, 
inter actions between a toxic agent (aflatoxin) 
and a pathogen [hepatitis B virus (HBV)] 
dramatically increase the risk of liver cancer 
(Groopman et al. 2005). However, researchers 
have not designed studies specifically to 
address potential interactions in the etiology 
of other chronic diseases, such as the poten-
tial interaction of toxicants (Rohrmann et al. 
2009) and microbial agents in colon cancer 
etiology. Environmental agents can be impor-
tant cofactors even in diseases for which a 
pathogen plays a primary role, as in cervi-
cal cancer, in which human papilloma virus 
(HPV) is the primary etiological factor but 
smoking may act as a cofactor (Castellsagué 
and Muñoz 2003). These examples illustrate 
the benefits of reincorporating infectious dis-
ease research into environmental health.
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divide between environmental and infectious 
disease programs. This programmatic separa-
tion has been problematic, exemplified in the 
conflict within the WHO over the revived use 
of DDT (dichloro diphenyl trichloro ethane) 
for malaria control in 2006 (Eskenazi et al. 
2009; van den Berg 2009).
Even within Public Health Service agen-
cies concerned with the environ ment, such 
as the National Institute of Environmental 
Health Sciences (NIEHS), research has not 
emphasized infectious disease. Competing 
niches in research, and the much earlier estab-
lishment of the National Institute of Allergy 
and Infectious Diseases (NIAID), may have 
contributed to this. Through the 1970s, 
politi cal decisions (e.g., the creation of the 
NIEHS National Toxicology Program and 
the U.S. EPA Superfund Program) formalized 
close inter actions between the research agenda 
of the NIEHS and the regulatory program 
of the U.S. EPA, further contributing to the 
NIEHS research agenda on toxicology and 
the exclusion of infectious disease research. 
The NIEHS expanded its purview into global 
environmental health in 2006, but none of 
the extra murally funded projects under this 
initiative have focused on infectious disease 
per se (Drew et al. 2008). 
Over the past 20 years, the NIEHS and 
NIAID have diverged in intra mural and 
extra mural research priorities (NIAID 2009). 
Although promising, the Ecology of Infectious 
Diseases Initiative (EID) coordinated by the 
National Science Foundation and the Fogarty 
International Center has failed to bridge the 
research gap between toxicology and infectious 
disease. According to its stated goal, the EID 
(National Science Foundation 2010) supports 
the development of predictive models and the 
discovery of principles governing the transmission 
dynamics of infectious disease agents. To that end, 
research proposals should focus on understand-
ing the ecological and socio-ecological determi-
nants of transmission by vectors or abiotic agents, 
the population dynamics of reservoir species, the 
transmission to humans or other hosts, or the cul-
tural, social, behavioral, and economic dimensions 
of disease communication. 
However, no projects funded by the EID to 
date have studied interactions between toxi-
cant exposures and infectious disease. 
NIEHS funding priorities and research 
agenda. The stated mission of the NIEHS 
(2009) is to “reduce the burden of human 
illness and disability by understanding how 
the environment influences the development 
and progression of human disease.” This has 
led to a concentration on basic science and 
training related to disease-oriented research 
and global environmental health. Intramural 
research at the NIEHS includes five programs: 
environmental biology, environ mental disease 
and medicine, clinical research, environ mental 
toxicology, and the National Toxicology 
Program. Extramurally, the top five funded 
areas of organ systems or disease research are 
respiratory, neuro degenerative and neuro-
developmental, endocrine (including breast 
cancer), cardio vascular, and immune system 
diseases or disorders. Basic science research 
funding focuses on laboratory-based inquiry 
more than on disease processes in the context 
of the environment or large populations. 
NIEHS training grants support research 
that aims to “understand how environmental 
exposures alter biologic processes and affect the 
risk of either disease development or the distri-
bution of disease in popu lations” (NIEHS 
2006). These training grants aim to support 
research not only on chemicals known to be 
environmental pollutants but also on “fungal 
or bacterially derived toxins due to ambient 
exposures” as well as those infectious and para-
sitic agents that are “disease co-factors with an 
environmental toxicant exposure” (NIEHS 
2006). Although the scope of the award 
includes this language, most funded projects 
to date do not encompass these areas. 
Problem formulation. Pathogens are not 
included in the current toxicological paradigm, 
despite their contribution to the etiology of 
environmental disease. Therefore, we developed 
a toxicological–pathogen conceptual paradigm 
as a framework for integrating toxicology and 
infectious disease research and theory. 
The Integrated Conceptual 
Paradigm for Environmental 
Disease Etiology
Figure 1 presents our integrated paradigm 
for environmental health, combining the 
toxicological paradigm (National Research 
Council Committee on Biological Markers 
1987) with aspects of conceptual models of 
infectious disease transmission (Anderson and 
May 1992). Our integrated model specifically 
incorporates potential interactions, in contrast 
to existing toxicological and infectious disease 
models that assume one agent causes one dis-
ease. In reality, disease etiology is more com-
plex, and in Figure 2, we adapt the Ottman 
model (Ottman 1996) for gene–environment 
interactions to demonstrate how two risk fac-
tors, specifically toxicants and pathogens, can 
interact to cause disease. Our integrated para-
digm (Figure 1) captures these possibilities 
by including inter agent interactions at several 
stages along the backbone of the toxicological 
paradigm, which models progression from an 
individual’s exposure to clinical disease. 
Some differences between the toxico-
logical paradigm and the infectious disease 
model challenge their integration. Although 
some epidemiological studies in environ-
mental health focus on populations [largely 
with ecological designs, e.g., those in air pollu-
tion research (Bell et al. 2009; Katsouyanni 
et al. 2009)], the classic toxicological paradigm 
models toxico kinetics and toxico dynamics at 
the level of the individual, generalizing from 
this level to a similarly exposed population. 
In contrast, models of infection are based on 
population-level probabilities of progress-
ing from exposure to infected, infectious, or 
immune/susceptible states. The concept of 
“risk transmission” is critical to infectious 
disease dynamics. In contrast, environ mental Figure 1. Integrated toxicological–pathogen conceptual paradigm for disease etiology.
Environment








































 A niche for infectious disease in environmental health
Environmental Health Perspectives • volume 118 | number 8 | August 2010 1167
toxicant transfers generally do not occur 
through direct person-to-person transmission. 
However, fomite transmission does occur for 
both infectious and toxic agents; pathogens may 
be transmitted via inanimate objects, and simi-
larly, workers may transport toxicants to their 
homes on vehicles or clothing (McDiarmid 
and Weaver 1993). Interindividual transmis-
sion of both infectious and toxic agents can 
occur through mother-to-child transmission, as 
in the case of HIV (human immuno deficiency 
virus) and the toxicants bisphenol A and mer-
cury (Barragan and Sibley 2003; Sakamoto 
et al. 2010; Schonfelder et al. 2002). 
In infectious disease modeling, the addi-
tional consideration of change in host sus-
ceptibility (or immune status) that occurs in 
the context of infection is critical. In contrast, 
toxicologists generally do not consider expo-
sure itself to modulate susceptibility, instead 
defining susceptibility factors as pre existing 
independent of exposure, such as genetic fac-
tors (National Research Council Committee 
on Biological Markers 1987). In some cases, 
enzyme induction may reduce or increase sus-
ceptibility on a transient basis by enhancing 
detoxification or activation, but this is usually 
a matter of degree and not absolute resistance 
in the immunological sense. No evidence 
exists that prior exposures to toxic agents 
prevent intoxication from later exposures; 
rather, cumulative exposures to most toxicants 
increase risks of adverse health outcomes. 
Another challenge is that in toxicologi-
cal models the quantity of an agent does not 
change over short periods of time in the 
environ ment, whereas infectious disease models 
must incorporate dynamics of growth or die-off 
of microbial populations. Pathogens are unique 
in that they can evolve such that the nature of 
their hazard changes (often rapidly), increas-
ing pathogenicity or virulence. Toxicants may 
degrade or accumulate in the environment and 
may change their hazardous properties through 
metabolic activation or deactivation within the 
organism (e.g., many carcinogenic chemicals) 
or through environmental bio methylation (e.g., 
mercury). These processes, however, are usually 
slower and much less substantial than the rapid 
changes typical of pathogenic organisms. 
The toxicological paradigm presumes a 
direct passage from exposure to disease. With 
pathogens, points of feedback add additional 
complexity. For example, exposure to influ-
enza may lead to development of immunity, 
clinical disease, or both. Toxicants can modu-
late these responses to infectious agents, as 
has been observed in gold miners exposed 
to both mercury and malaria (Silbergeld 
et al. 2005). Mercury affects host immune 
response, which can lead to increases in the 
incidence or clinical progression of malaria in 
a population (Gardner et al. 2009). We have 
incorporated these important feedbacks into 
our paradigm. As toxicology and infectious 
disease move toward integration, the state-of-
the-art methods developed in understanding 
infectious disease ecology (e.g., using the basic 
reproductive number, R0, to gain insight into 
population-level infectious disease dynamics) 
should be considered. 
Incorporating Pathogens in the 
Toxicological Paradigm
Potential barriers to integration in a common 
framework. Different meanings of the same 
terms. The disconnect between toxicology 
and infectious disease research is reinforced by 
inconsistencies in language and terminology. 
In toxicology, “exposure” is defined as exter-
nal to the body; “dose” refers to the internal-
ized level of a contaminant. Toxicokinetic 
processes occurring after internalization must 
be considered prior to impution or measure-
ment of concentrations at sites of toxic 
action. In the language of infectious disease 
and immunology, “exposure” has different 
meanings. Nasal carriage of Staphylococcus 
aureus bacteria, for example, is often termed 
“exposure,” without distinction as to whether 
this is transient superficial contamination or 
a reflection of pathogen replication on an 
external body surface. Exposure in infectious 
disease also can refer to events after a foreign 
antigen is internalized and processed for pre-
sentation to the immune system, often meas-
ured serologically (e.g., through anti bodies). 
The same biomarker—an antibody to a toxic 
agent (e.g., a hapten)—would be interpreted 
in toxicology as a measure of internal dose. In 
infectious disease, the concept of “exposure” 
is more general, hampering communication 
with toxicology and complicating ability to 
interpret the literature.
Lack of a common surveillance system. 
Environmental health surveillance systems 
focus on diseases related to the environ ment 
and on environmental exposures (International 
Epidemiological Association 2001; Thacker 
and Stroup 1996). Important environmen-
tal health surveillance programs include the 
Centers for Disease Control and Prevention 
(CDC)’s National Environmental Public 
Health Tracking Program (EPHT), National 
Biomonitoring Program (NBP), and National 
Health and Nutrition Examination Survey 
(NHANES). These programs differ: NBP 
collects data on biomarkers of exposure, 
NHANES collects information on both bio-
markers of exposure and health status, and 
EPHT collects, analyzes, integrates, and dis-
seminates data on exposures to environ-
mental pollutants and potentially related 
health effects (CDC 2010). In contrast, infec-
tious disease surveillance programs such as 
ProMED, FluView, and the WHO’s Global 
Outbreak Alert and Response Network are 
primarily response driven, based on detection 
of pathogens known to be associated with 
outbreaks or epidemics (CDC 2001, 2009; 
WHO 2009). Furthermore, the two fields dif-
fer in application of animal surveillance sys-
tems as sentinels for exposures or disease. In 
toxicology, animal sentinels have been used 
to detect specific hazardous conditions ever 
since canaries were carried into coal mines; 
more recent examples include tracking lead 
levels in wild rodents (Talmage and Walton 
1991) or household dogs and cats (Berny et al. 
1995). Infectious disease research incorpo-
rates animal sentinels more fully because of 
the close links between zoonotic pathogens 
and human health. For example, researchers 
track Hantaan virus using rats (Childs et al. 
1985; Mills et al. 2009) and West Nile and 
influenza A viruses using wild birds (Liu et al. 
2009; Munster and Fouchier 2009). Despite 
the potential utility of combining data from 
animal sentinels for integrated research, there is 
a lack of sufficient overlap and communication 
between the fields of animal and human dis-
ease research (Halliday et al. 2007; Rabinowitz 
et al. 2005). In general, common databases 
that combine information on both toxicant 
Figure 2. Four potential scenarios showing potential 
causality and interactions between pathogens and 
toxicants in disease etiology. (A) A toxicant and 
a pathogen may both be required to act together 
to cause a disease. (B) Either a pathogen or a 
toxi cant alone is sufficient to cause the disease. 
(C) A chemi cal toxicant can modify the association 
between a pathogen and a disease. (D) A pathogen 
can modify the association between a chemical 
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and pathogen exposures are lacking. There are 
examples where cross over between infectious 
disease and environmental health surveillance 
could increase capacity for interdisciplinary 
studies. For example, NHANES separately 
assesses exposures to environmental toxi cants 
such as mercury (McDowell et al. 2004) and 
prevalence of hepatitis E virus sero positivity 
(Kuniholm et al. 2009), but NHANES has not 
been used to test inter actions between patho-
gens and toxicant exposures. 
Lack of defined methods for integrative 
risk assessment. Risk assessment is a key tool in 
environmental health sciences, using toxicology 
in determining risks to individuals or popula-
tions through the steps of hazard identifica-
tion (determining if an agent potentially poses 
a threat if persons were to be exposed to it); 
exposure assessment (considering if and how 
people might come into contact with the haz-
ardous agent); and dose–response assessment 
(determining relation ships between the dose 
of the agent and adverse biological responses). 
Taken together, this information leads to 
the fourth step: characterizing the risk of the 
agent for given populations. The application 
of risk assessment methodologies to pathogens, 
although not straightforward, is evolving.
The emphasis on chemical toxicants at the 
U.S. EPA has facilitated the development of 
increasingly complex risk assessment method-
ologies. In comparison, assessment of pathogen 
risks has been applied primarily to food safety 
issues (Mota et al. 2009) but generally is much 
less developed largely because of the complexity 
of pathogen development and infectious disease 
transmission in the environment. The dynamic 
nature of microbial populations in terms of 
number and state, as discussed above, prevents 
direct application of toxicological models to 
infectious disease risk assessment (Ross and 
McMeekin 2003). Arguments against micro-
bial risk assessment cite the need for extensive 
information about bacterial behavior under 
particular conditions, details of these condi-
tions, and host responses in order to model 
risk (Toze et al. 2010). At present, the field of 
microbial risk assessment offers relatively few 
guidelines for incorporating data from mul-
tiple studies or at multiple levels of analysis, in 
contrast to recent guidelines for chemical risk 
assessment (National Research Council 2009). 
As a result, few microbial risk-assessment– 
based policies have been implemented. The 
lack of formal risk assessment methods for 
pathogens has posed considerable challenges 
to regulatory agencies, such as in the case of the 
Food and Drug Administration’s attempts to 
assess risks to human health associated with use 
of antimicrobials in animal feeds (Aarestrup 
et al. 2008). 
Moreover, these differences in risk assess-
ment can impede policy decisions that require 
a balancing of risks between microbial and 
chemi cal exposures, as evidenced in the 
trade-offs between water borne arsenic and 
cholera in Bangladesh (Lokuge et al. 2004). 
Our integrated paradigm could help to 
advance research to address these barriers to 
integrated risk assessment. 
Sample size concerns. In designing studies 
to evaluate pathogen–toxicant inter actions, 
consideration of sample size is critical. A 
study sufficiently powered to detect the main 
effect from one agent may be under powered 
to detect an inter action of similar magnitude 
between two agents (Brookes et al. 2004). 
Biostatistical litera ture on study design for 
subgroup inter actions in clinical trials or for 
gene–environment interactions may prove 
rele vant to designing the research we propose 
here. These works suggest increasing sample 
size 4-fold to power a study to test inter action 
on the additive scale (Brookes et al. 2004) 
or altering sampling strategy to improve effi-
ciency (Weinberg 2009).
Unifying factors lending support for an 
integrated framework. Focus on upstream 
interventions. Important unifying factors sup-
port overcoming the barriers discussed above 
to integrate toxicology and infectious disease 
research. Fundamentally, both fields promote 
prevention of exposure as the most efficient 
way to reduce disease risks. In environ mental 
health, this focus on preventing exposure is 
exemplified in the “hierarchy of controls,” in 
which interventions at the source of exposure 
are preferred to reduce or eliminate human 
exposure. In contrast, infectious disease con-
trol efforts largely focus on receptors, through 
achieving herd immunity by reducing the pool 
of susceptible individuals through quaran tine 
or vaccination. Some interventions before 
actual infection, such as metaphylaxis (treat-
ment in the absence of disease), can have nega-
tive consequences, such as driving selection of 
drug resistance within the pathogen commu-
nity (Aarestrup et al. 2000). Some of the most 
effective opportunities for primary prevention 
in infectious disease, prior to exposure of a 
human or animal host, often involve environ-
mental inter ventions such as elimination of 
vector habitats and protection of food or water 
sources. This shared focus on the value of 
upstream interventions is an important driver 
for integrating infectious disease into environ-
mental health. 
Spatial context. Researchers in environ-
mental health have developed and employed 
methods for the study of spatially distributed 
risks, including cluster analysis and small-area 
studies that can detect geographically defin-
able areas of elevated exposures or disease in 
certain populations. These approaches rely 
on the assumption that proximity to a toxi-
cant source is a risk factor for exposure. For 
example, studies using spatial techniques have 
found associations between distance from 
highways (as a proxy for exposure to air pollu-
tants) and symptoms of respiratory distress 
(Boothe and Shendell 2008; Braback and 
Forsberg 2009). The same tools have proven 
useful in studying infectious diseases influ-
enced by spatial or landscape factors (Kitron 
1998), as well as identifying risk factors 
for disease spread (Eisen et al. 2007; Glass 
et al. 1995). Considering its utility for both 
environ mental health and infectious disease 
studies, spatial modeling has the potential to 
be a cornerstone in the development of inte-
grated research.
Quantitative models of exposure. Human 
exposure modeling that incorporates all poten-
tial routes of exposure is a central aspect of risk 
assessment. Quantitative models are used to 
estimate toxicant exposure at the ambient or 
personal level and are valuable when local-scale 
measurements are inappropriate, unfeasible, or 
cost-prohibitive. For example, food consump-
tion data enable estimation of pesticides con-
sumed or probability of exposure to food borne 
pathogens under given conditions. Modeling 
is applied in infectious disease research for 
estimating disease transmission within a 
population and for comparing various public 
health interventions. These models typically 
estimate population-level changes and transi-
tions through defined disease states using dif-
ferential equations. Like spatial modeling, this 
shared approach provides an opportunity for 
increased collaboration and communication. 
Biomarkers and omics. Biomarkers are 
another unifying factor between these fields. 
Biomarkers are measurable molecular changes 
in the body (e.g., blood, tissue) that provide 
information on three main characteristics: 
exposure, susceptibility, and disease (National 
Research Council Committee on Biological 
Markers 1987). They are used as indicators 
of events along the toxicological pathway, 
including toxico kinetics (exposure, internal 
dose, and biologically effective dose) and 
toxico dynamics (early biological effect, altered 
structure and function, and clinical disease) 
(National Research Council Committee on 
Biological Markers 1987). Infectious disease 
research has long used biomarkers through 
the direct measure ment of pathogens in body 
compartments or excreta and more recently 
through serological analysis of antibodies to 
pathogens. Biomarkers also can be used to 
distinguish between different genetic strains 
of pathogens, which can help to identify the 
source or transmission pathway of a disease. 
Our proposed integrated paradigm incorpo-
rates both infectious agents and toxicants as 
potential exposures on the pathway to disease. 
New technologies empowered by genome 
projects have generated considerable atten-
tion in both toxicology and infectious dis-
ease. Through the National Center for 
Toxicogenomics at the NIEHS, which has 
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the goal of identifying genetic poly morphisms 
that modulate response pathways, the field 
of toxicology has adopted a systematic 
approach to omics that is relevant to patho-
gens as well. These technologies have pro-
duced valuable biomarkers of exposure and 
early biological responses in clinical studies 
(Beger et al. 2010). However, the predictive 
power of many biomarkers is largely unvali-
dated, potentially producing misleading infor-
mation (Nilsson et al. 2009). Moreover, in 
the absence of more traditional information 
on the context of toxicant exposures, omics 
biomarkers may be difficult to interpret for 
retrospective exposure assessment (Scheepers 
2008). These omics technologies promise to 
deliver a molecular “footprint” for risk factors 
that could be identified and traced through 
the steps of the traditional toxicological para-
digm (Guyton et al. 2009; Ramos et al. 2007; 
Schnackenberg and Beger 2006; Wetmore 
and Merrick 2004). Attempts to produce this 
“holy grail” include relatively simple analy-
ses of base-pair substitutions (Lasky and 
Silbergeld 1996) and collection of dense data 
sets derived from micro array gene expression 
data and proteomics (Frijters et al. 2007). 
To a large extent, these applications have 
used cross-sectional measurements, which 
may explain why surprisingly little value has 
been extracted in terms of explaining dynamic 
events between exposure and outcome. A 
recently published analysis of microarray gene 
expression data for six carcinogens (of both 
chemical and pathogen origin) demonstrates 
the importance of measuring these signals 
over time in order to understand dynamic 
events between exposure and outcome 
(Mathijs et al. 2009). In contrast, the use of 
omics methods in infectious disease research 
has been extensive and valuable in contrib-
uting to understanding events from expo-
sure source to disease. Pathogen “exposure” 
often is defined very precisely by genotype, 
a level of analysis that provides important 
information on agent source and networks 
of host–host transmission. For example, 
our understanding of methicillin-resistant 
Staphylococcus aureus (MRSA) dissemina-
tion in humans and animals depends on the 
use of genotypic methods such as multi locus 
sequence testing to identify outbreaks of dis-
ease (Kock et al. 2009) and to detect other-
wise unrecognized disease clusters (Mellmann 
et al. 2006). Whole-genome methods have 
revealed early evolutionary changes in the 
H1N1 influenza A virus (Ramakrishnan 
et al. 2009; Vincent et al. 2009) and differ-
ential virulence genes in porcine enteropathic 
Escherichia coli (Bruant et al. 2009). Genetic 
analysis of Campylobacter jejuni bacteria has 
provided insight into observed associations 
between C. jejuni infection and auto immune 
peripheral neuropathies (Dingle et al. 2001).
Examples of Research 
Exemplifying the Integrated 
Paradigm
Pathogen–toxicant interactions. Several chronic 
diseases have been strongly associated with 
toxic agents. Pathogens can also cause some 
of these same diseases, as well as interact with 
toxicants in the etiology of diseases that are 
typically considered to be toxicant associated. 
For example, NIEHS research and funding 
highlight cancer as a disease associated with 
gene–toxicant interactions. However, patho-
gens, particularly viruses, are increasingly being 
recognized as carcinogens (Fontham 2009; 
Schulz 2009).
A century ago, Rous (1910) provided 
evidence of a role for viruses in cancer, but 
dogma during the next several decades was 
dominated by resistance to this possibility 
(Epstein 1971). More than 70 years ago, Rous 
and colleagues (Rogers and Rous 1951; Rous 
and Kidd 1936, 1938) also presented evidence 
that viruses and chemical toxicants can inter-
act in carcino genesis. The Shope papilloma 
virus causes warts or papillomas on rabbits’ 
skin (Shope and Hurst 1933); in some animals 
these papillomas were observed to progress 
to malignant carcinomas after several months 
(Rous and Beard 1935). Meanwhile, coal tar 
applied to rabbits’ skin was observed to result 
in warts, which occasionally became malig-
nant after longer time periods (Rous and Kidd 
1938). In a combined experiment of coal tar 
application to rabbit skin followed by injec-
tion of Shope papilloma virus, Rous and Kidd 
(1938) observed that carcinomas developed 
more rapidly than under either exposure alone, 
indicating an interaction between chemical 
and viral carcinogens. 
Despite this early evidence that papil-
loma viruses can interact with chemicals in 
carcino genesis in animals, little research on 
pathogen–chemical interactions in cancer has 
been performed. Assessment of potential inter-
actions of chemicals with HPV was limited by 
delayed recognition of HPV as a carcinogen. In 
the late 1980s Layde and Broste (1989) real-
ized that the potential role of smoking in cervi-
cal cancer etiology could not be appropriately 
assessed without recognition of the relevant 
infectious agent as a potential confounder or 
effect modifier. Now that HPV has been estab-
lished as the primary risk factor for cervical 
cancer, epidemiological methods for studies of 
potential chemical cofactors such as smoking, 
oral contraceptive use, and diet have improved, 
and remaining methodological challenges 
have been identified (Castellsagué and Muñoz 
2003; Castellsagué et al. 2002). Recent studies 
that have assessed the risk of smoking while 
accounting for HPV status provide evidence 
that smoking may act as a cofactor in cervical 
cancer (Castellsagué et al. 2002; Castellsagué 
and Muñoz 2003). Several potential biological 
mechanisms have been proposed for this inter-
action, including nicotine causing DNA dam-
age in the cervix and chemical modulation of 
immune response to HPV (Castellsagué et al. 
2002; Gunnell et al. 2006). 
Evidence is emerging for a potential role 
of infectious agents in other chronic diseases. 
Bidirectional interactions have been observed 
for mercury and pathogens. Mercury can alter 
the immune response to coxsackie B3 virus 
(CB3V) (Ilbäck et al. 1996), with resulting 
increases in post infection pathology, includ-
ing auto immunity (Nyland et al. 2004; South 
et al. 2001). Also, infection by CB3V alters the 
toxico kinetics of mercury, resulting in increased 
levels of mercury in heart tissue (Frisk et al. 
2008). These examples indicate that research 
on the etiology of chronic disease can benefit 
from an inter disciplinary approach that investi-
gates both infectious agents and environmental 
toxicants and their potential inter actions. 
Limited research suggests interactions 
between toxicants and severity of infectious 
disease or acquisition of resistance to infectious 
diseases. Studies of coexposures to mercury and 
malaria (in both animal models and human 
populations) suggest that mercury may inhibit 
acquisition of immunity to malaria (Crompton 
et al. 2002; Silbergeld et al. 2005), but more 
research is needed on this and related topics. 
Key example: toxicant and viral inter-
actions in liver cancer etiology. Research prog-
ress in the area of hepatocellular carcinoma 
(liver cancer) is a key example of research that 
successfully applies the toxicological model 
and other tools, such as biomarkers and 
genomics, to studying both environmental 
toxicants and pathogens in disease etiology 
(Groopman et al. 2005). This work helped 
motivate our research; it illustrates how our 
integrated paradigm can be applied to explore 
interaction between toxicants and infectious 
disease in an environmental context. 
Early epidemiological studies indicated 
that aflatoxin, a fungal toxin that is a contami-
nant of food, was associated with increased 
risk of liver cancer (Groopman et al. 2005). 
However, these studies did not account for the 
potential role of hepatitis viruses (Groopman 
et al. 2005). Separate studies were conducted 
on HBV without assessing aflatoxin exposure. 
In 1981, results from a prospective cohort 
study of 22,707 men in China indicated that 
those men who tested positive for hepatitis B 
surface antigen were 223 times more likely 
to develop liver cancer than those men who 
tested negative (Beasley et al. 1981). The 
assessment of aflatoxin and hepatitis exposures 
separately did not account for the possibility 
that these two agents might interact with each 
other. The first investigations of coexposures 
to aflatoxin and HBV used biomarkers of 
exposure to both risk factors in a case–control 
Feingold et al.
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study nested within a cohort of 18,244 people 
in Shanghai, China (Qian et al. 1994; Ross 
et al. 1992). Although aflatoxin and HBV 
each were independently associated with liver 
cancer, a dramatic synergistic interaction was 
observed between aflatoxin exposure and HBV 
infection (Table 1) (Qian et al. 1994), which 
has been replicated in additional studies (Wild 
and Montesano 2009). Several mechanisms 
may contribute to development of liver cancer; 
genetic factors, exposures to other toxicants 
such as alcohol, and other forms of hepatitis 
may play a role (Cha and Dematteo 2005). 
The potential role of genetic susceptibility fac-
tors of the host, as well as pathogen genetic 
factors (e.g., mutations in the HBV genome), 
highlights the importance of incorporating 
the newer techniques of genomics into cross-
disciplinary research (Groopman et al. 2005).
Figure 3 shows the molecular mecha-
nisms by which HBV and aflatoxin may act 
both independently and synergistically in 
liver cancer etiology (Groopman et al. 2005). 
Although these mechanisms are not com-
pletely understood, they have been charac-
terized through the use of bio markers (Cha 
and Dematteo 2005; Groopman et al. 2005; 
Wild and Montesano 2009). This integrated 
biomarker research has led to the identification 
of potential strategies for liver cancer preven-
tion that address the role of either the viral or 
toxicant exposures or both (Groopman et al. 
2005; Wild and Montesano 2009). These 
strategies include HBV vaccination, reduction 
of aflatoxin exposure, and, notably, chemo-
prevention by altering aflatoxin metabolism, 
which may be important in those populations 
where primary prevention is currently diffi-
cult (Groopman et al. 2005). Biomarkers have 
been used as intermediate end points to opti-
mize the evaluation of these agents in trials 
(Groopman et al. 2005). 
Colon Cancer: Potential 
Research Following the 
Integrated Paradigm
As with liver cancer, colon cancer research 
might benefit from interdisciplinary investiga-
tion of potential microbial–chemical inter -
actions. The potential for such inter actions in 
colon cancer was hypothesized by Weisburger 
in 1971 but not directly tested. Weisburger 
(1971) speculated about several possible 
mechanisms of colon carcino genesis involving 
diet, activity of gut flora, or both. As one pos-
sibility, he hypothesized that bacterial action 
might release active intermediates from 
ingested chemicals such as aromatic amines 
(Weisburger 1971). Recent research indicates 
that both microbes and chemi cals may be risk 
factors for colon cancer, but these have been 
explored as separate entities. Epidemiological 
studies, including studies using DNA adducts 
as biomarkers, indicate that exposure to 
hetero cyclic amines (HCAs) and polycyclic 
aromatic hydro carbons (PAHs) found in 
well-done meat may be associated with risk of 
colon cancer via DNA damage (Ramesh et al. 
2004; Rohrmann et al. 2009; Sinha et al. 
2005). Genetic risk factors, such as polymor-
phisms of the UDP-glucuronosyltransferase 
1A7 gene, may interact with these dietary 
chemicals in colon cancer etiology (Butler 
et al. 2005). On a separate track, recent micro-
biology research indicates that entero toxigenic 
Bacteroides fragilis bacteria may contribute 
to colitis (Rabizadeh et al. 2007) and to the 
development of colon tumors via TH17-
mediated inflammation (Wu et al. 2009). 
Thus, bacterial-associated inflammation of the 
colon (colitis) may contribute to colon cancer, 
as viral-associated inflammation of the liver 
(hepatitis) contributes to liver cancer. HCAs 
and PAHs may exhibit chemical carcino-
genicity in the colon, as aflatoxin exhibits liver 
carcino genicity. Given the toxicant–pathogen 
synergy in liver cancer, we hypothesize that 
similar interactions may occur in colon can-
cer etiology. To test this hypothesis, a study 
could explore potential interactions between 
ETBF (entero toxigenic Bacteroides fragilis)
bacteria and HCAs or PAHs. Our integrated 
paradigm provides a common framework for 
collaborators to explore such interdisciplinary 
research questions. 
Recommendations for Future 
Funding and Research
Research initiatives should be designed to foster 
collaborations among researchers in infectious 
disease and environmental health, specifically 
toxicology. Large, population-based studies 
should include sample collections that enable 
assessment of exposures to environmental 
agents as well as to pathogens. In experimental 
research, the assessment of immuno toxicity in 
animal models should go beyond charac teriza-
tion of immune parameters (i.e., cell subsets, 
cytokine production, cell surface markers) and 
standard measures of function (i.e., sheep red 
blood cell response, lipopolysaccharide stimu-
lation) to models that incorporate analysis of 
response to infectious agents. 
In concert with the strategic plan of the 
NIEHS, collaboration with other agencies 
within the National Institutes of Health 
should be promoted to stimulate cross- 
disciplinary research (NIEHS 2006). A high 
Table 1. Combined effects of HBsAg positivity and presence of urinary aflatoxin biomarkersa on risk of 
hepato cellular carcinoma in Shanghai. 
Aflatoxin negative Aflatoxin positive
HBsAg Cases Controls RRb (95% CI) Cases Controls RRb (95% CI)
Negative 5 134 1.0 13 102 3.4 (1.1–10.0)
Positive 9 24 7.3 (2.2–24.4) 23 7 59.4 (16.6–212.0)
Abbreviations: CI, confidence interval; HBsAg, hepatitis B surface antigen. Reprinted from Qian et al. (1994) with permission 
from the American Association for Cancer Research.
aAFB1, AFP1, AFM1, and AFB1-N7-guanine. bAdjusted for cigarette smoking.
Figure 3. Potential molecular mechanisms of interaction between HBV and aflatoxin in the development 
of hepatocellular carcinoma, as elucidated by several biomarkers. HBsAg, hepatitis B surface antigen. 
Reprinted from Groopman et al. (2005) [Aflatoxin and hepatitis B virus biomarkers: a paradigm for complex 
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priority should be given to cross-disciplinary 
research on those diseases for which toxico-
logical and pathogen etiologies have separately 
been identified. This may be accomplished 
best through the issuance of joint requests for 
proposals and the creation of specific study 
sections.
The integrated paradigm presented in this 
review could guide education and training of 
environmental health researchers and practi-
tioners. Improving interdisciplinary under-
standing is critical—and environ mental health 
professionals should fully engage in dialogue, 
research, and policy development in these 
areas. To achieve this, formal training in inte-
grated research designs must be brought more 
overtly into environmental health curricula. 
Improving communication among researchers 
is instrumental in building and maintaining 
bridges across separated fields. Conferences 
jointly sponsored by core government and 
professional organizations in environ mental 
health and infectious disease can foster net-
working and collaboration, along with grant 
programs and other funding. This provides 
a venue for the sharing of research to spark 
ideas for studies to investigate possible inter-
actions. Successful models, such as EID, offer 
opportunities for expansion.
Integrating surveillance systems—of both 
animals and humans—is critically impor-
tant, and improving cross-utilization and 
communication among existing surveillance 
programs is a first step. Collaborative efforts 
will be needed to design these systems for 
applicability in both infectious disease and 
toxicology. Databases of animal and human 
health surveillance data should be linked, and 
barriers of incompatible forms of data collec-
tion and management should be eliminated 
(Scotch et al. 2009). Increased support for 
CDC biomonitoring and surveillance pro-
grams (NHANES, NBP, EPHT) should be 
allocated to ensure funds for sample collection 
and analysis of both chemicals and pathogens. 
Conclusions
The toxicological paradigm has not been 
engaged previously as a mechanism for under-
standing the relationship between environ-
mental health and infectious diseases. 
Recognizing and incorporating the common 
tools of spatial analysis, risk assessment, expo-
sure modeling, biomarker analysis, and genom-
ics will enhance a comprehensive approach to 
studying the role of both toxi cants and patho-
gens in chronic disease etiology. Reframing 
the toxicological paradigm provides a roadmap 
for interdisciplinary research and a guide for 
research conducted at this important interface, 
and may help public health practitioners to 
weigh the risks posed by the constant barrage 
of environmental exposures on the human sys-
tem and determine how to best mitigate them. 
Funding agencies, academic departments 
of environmental health, and researchers in 
related fields need to work together to broaden 
the scope of environ mental health and to drive 
innovative research. 
In a broader sense, the limits of the current 
focus of environmental health on toxicology 
do not apply only to the exclusion of patho-
gens. Classic reductionist thinking in toxicol-
ogy focuses on “one toxicant, one outcome” 
research. This neglects not only infections but 
also other comorbidities that burden much of 
the U.S. and worldwide populations, such as 
obesity and diabetes. With most of the U.S. 
population taking drugs daily to treat these 
comorbidities, research must account for the 
realities of complex exposure scenarios. If basic 
research is to increase our ability to predict the 
consequences of exposure to environmental 
chemicals, we must embrace non reductionist 
thinking and design experimental models that 
emulate human experience, including but not 
limited to the interactions between infections 
and toxicological exposures.
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